ADICON HOLDINGS cash and new share strategic acquisition involves an investment of 230 million RMB

AASTOCKS
2025.05.06 14:42

ADICON HOLDINGS (09860.HK) announced a strategic investment to acquire 100% equity of Yuan De Wei Kang (engaged in the research and production of blood diagnostic reagents) from an independent third party for a consideration of RMB 179 million (equivalent to HKD 191 million), which will be paid through the issuance of up to 29,025,700 consideration shares at an issue price of HKD 6.58, representing a discount of 12.15% compared to the last trading day (6th).

At the same time, the group's mainland ICL (Independent Clinical Laboratory) subsidiary, Hangzhou ADICON, is acquiring 100% equity of Yuan De You Qin (specializing in medical testing services with expertise in blood testing) from an independent third party for a cash consideration of RMB 50 million

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.